Skip to content

Investors / Press Releases


The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.


Filter Releases
 
Press Releases
Date Title and Summary View
Jan 30, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") for gross proceeds of approximately $70.0 million, before deducting the underwriting discounts and commissions and other estimated o...
Jan 29, 2018
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a registered underwritten public offering of its American Depositary Shares.  All of the shares in the proposed offering are to be sold by Amarin.  The offering is subject to market conditions, and there can be no assuranc...
Jan 23, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that its REDUCE-IT cardiovascular outcomes study has reported and documented more than 90% of t...
Jan 17, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics, today announced that a clinical trial of Vascepa® (icosapent ethyl) capsules in a patient population with severe hypertriglyceridemia (TG &...
Jan 4, 2018
Unaudited Full-Year 2017 Net Product Revenue Estimated Between$177 and $180 Million, Exceeding Upper End of Previously Provided Guidance,with Fourth Quarter Estimate Between $51 and $54 Million Anticipate 2018 Net Product Revenue Growth of Approximately$50 Million or $230 Million for Full-Year 2018 Net Product Revenue with Guidanceto Be Update...
Dec 19, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health,  today announced REDUCE-IT cardiovascular outcomes study clinical sites have been instructed to begin scheduli...
Dec 18, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a ...
Nov 14, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced data analysis orally presented today at the American Heart Association (AHA) 2017 Scientific Sessions...
Nov 13, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced an oral presentation titled, "Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory ...
Nov 13, 2017
Higher Rates of Myocardial Infarction (Heart Attack) and Revascularization Procedures in Patients with High Triglycerides Were Drivers of the Composite Outcome MACE Rate 35% Higher in Patients Who, Despite Statin Therapy, Have Elevated Triglyceride Levels Cost of Health Care Nearly 15% Higher in this Higher Risk Patient Population BEDMINSTER...
Nov 7, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a ...
Nov 1, 2017
Nov 1, 2017
Record-High Net Product Revenue of $47.1 Million in Third Quarter Management to Host Conference Call Today at 8:00 a.m. ET BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to impr...
Oct 25, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the co...
Sep 25, 2017
BEDMINSTER, N.J., DUBLIN, Ireland, and TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and HLS Therapeutics Inc. ("HLS"), announced today an exclusive agreement between the parties to register, commercialize and distribute Vascepa® (icosapent ethyl) capsules in Canada. Amarin and HLS anticipate submitting an ...
Page:
...
Next Last
 
= add release to Briefcase